Quantitative in situ interactomics for clinically meaningful immune checkpoint research
Expression alone does not always capture immune checkpoint biology in tissue. For translational studies, what often matters is whether checkpoints are functionally engaged and which signalling states are active within the tumor–immune interface.
Yet, many tissue workflows still depend on IHC expression scoring, which can vary across sites due to staining conditions, intensity-dependent interpretation, and reader-to-reader variability. This can make cross-cohort comparisons harder and complicate the definition of consistent stratification thresholds.
QF-Pro® enables direct quantification of immune checkpoint-related receptor–ligand engagement and post-translational modifications (PTMs) in situ, providing a functional validation step after discovery. The technology delivers standardized quantitative outputs with the potential to support cut-off definition for translational and biomarker-driven studies.

QF-Pro® quantifies immune checkpoint receptor–ligand engagement directly in fixed samples and converts these functional events into standardized interaction scores. Across multiple tumor contexts, high vs low engagement patterns can separate patient groups, supporting stratification analyses and cut-off definition for translational studies.
Key Benefits of the QF-Pro®:
- In situ validation of immune checkpoint biology directly in FFPE tissue
- Standardized, reproducible quantitative outputs suitable for cohort-level comparisons
- Supports cut-off definition to enable stratification and biomarker-driven study design
- Clear functional readouts (interaction and activation states) to guide translational decisions
- Captures spatial heterogeneity through interaction/activation mapping across regions of interest (ROIs)
Validated biomarkers:
Receptor-Ligand Engagement (Immune Checkpoints)
- PD-1/PD-L1
- CTLA-4/CD80
- TIGIT/CD155
- LAG3/MHC-II
- TIM3/Gal9
- OX40-OX40L
Protein-protein interactions (PPIs)
- CD69/Gal1
- HER2/HER3
- HER3/EGFR
- HER2/EGFR
- Podocalyxin/Beta-catenin
- Podocalyxin/NHERF-1
- PD-1/SHP-2
- Cyclin E/CDK2
- Beta-catenin/E-cadherin
- PKB/PDK1
Post-translational modifications (PTMs)
- Akt/PKB activation state (pT308)
- EGFR activation state (pY1068)
- Rb activation state (pS807/811)
- STAT3 activation state (pY705, pS727)

Meet HAWK Biosystems in Germany – Summer 2026
HAWK Biosystems and Future Lab Innovations will hit the road together and visit research centers and scientific events to:
- Introduce QF-Pro® in immune-oncology contexts
- Discuss immune checkpoint biomarker validation strategies and study design
- Explore how in-situ interactomics can complement your existing discovery pipeline
Schedule a visit to your facility now


